Skip navigation
Skip navigation

Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza

Hurt, Aeron; Kelly, Heath


A debate about the market-leading influenza antiviral medication, oseltamivir, which initially focused on treatment for generally mild illness, has been expanded to question the wisdom of stockpiling for use in future influenza pandemics. Although randomized controlled trial evidence confirms that oseltamivir will reduce symptom duration by 17-25 hours among otherwise healthy adolescents and adults with community-managed disease, no randomized controlled trials have examined the effectiveness...[Show more]

CollectionsANU Research Publications
Date published: 2016-06
Type: Journal article
Source: Emerging infectious diseases
DOI: 10.3201/eid2206.151037
Access Rights: Open Access


File Description SizeFormat Image
01_Hurt_Debate_Regarding_Oseltamivir_2016.pdf1.12 MBAdobe PDFThumbnail

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator